Systemic and Endocrine Effects of Endothelin in Humans
The endothelium is the key to a complex system of neural and humoral factors modulating vascular smooth muscle tone by producing both relaxing and constrictive factors including the three currently known members of the endothelin family, endothelin-1 (ET-1 ), ET-2 and ET-3. These three structurally related peptides correspond to two types of receptors, designated ETA and ETB. The hemodynamic effects of endothelin-1 have been extensively studied in various animal models. Furthermore an impressive bulk of data has been obtained in vitro and in vivo concerning the recently recognized importance of endothelins as regulatory factors in various endocrine tissues. Although endothelin-1 is secreted mainly abluminally  and may play a paracrine rather than an endocrine role, experiments evaluating the effects of pharmacological doses in man may help to interpret the effect of increased plasma concentrations of ET-1 which have been observed in various clinical conditions . However, due to the difficulty arising from the use of such a potent vaso-pressor agent on an experimental basis in humans comparatively few such experiments have been performed in man.
KeywordsAtrial Natriuretic Peptide Adult Respiratory Distress Syndrome Plasma Aldosterone Concentration ACTH Stimulation Test Human Cerebrospinal Fluid
Unable to display preview. Download preview PDF.
- 2.Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhäusl W, Binder BR (1992) Polar Secretion of Endothelin-1 by Cultured Endothelial Cells. J Biol Chem 267:16 066–16 068Google Scholar
- 3.Hutchison FN (1989) Endothelin: a new role for an old friend? J Lab Clin Med 122: 126–127Google Scholar
- 11.Haynes WG, Webb DJ (1993) Venoconstriction to endothelin-i in humans: role of calcium and potassium channels. Am J Phyciol 265: H1676 - H1681Google Scholar
- 13.Kiowski W, Löscher TF, Linder L, Bühler FR (1991) Endothelin-i-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 83: 469–475Google Scholar
- 14.Kiowski W, Linder L, Stoschitzky K, Pfisterer M, Burckhardt D, Burkart F, Bühler FR (1994) Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-i in clinically healthy smokers. Circulation 90: 27–34PubMedGoogle Scholar
- 16.Vierhapper H, Hollenstein U, Roden M, Nowotny P (1993) Effect of endothelin-, in man - impact on basal and stimulated concentrations of LH, FSH, TSH, GH, ACTH and PRL. Metabolism 42: 902–906Google Scholar
- 19.Weitzberg E, Ahlborg G, Lundberg JM (1993) Differences in vascular effects and removal of endothelin-i in human lung, brain, and skeletal muscle. Clin Physio113: 653–662Google Scholar
- 34.Vierhapper H, Hollenstein U, Gessl A, Roden M, Nowotny P, Waldhäusl W (1994) Effect of endothelin-i on basal and stimulated concentrations of pituitary hormones in healthy men with and without pretreatment with nifedipine. 38th symposium, Deutsche Gesellschaft für Endokrinologie, Würzburg, 2–5 March 1994. Exp Clin Endocrinol 102 [Suppl 1]: 116 (abstract)Google Scholar